Jefferies Financial Group Inc. Invests $11.60 Million in Xencor, Inc. $XNCR

Jefferies Financial Group Inc. purchased a new position in Xencor, Inc. (NASDAQ:XNCR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 720,440 shares of the biopharmaceutical company’s stock, valued at approximately $11,599,000.

Several other large investors also recently bought and sold shares of the business. Allworth Financial LP purchased a new position in Xencor in the 2nd quarter worth approximately $55,000. Tower Research Capital LLC TRC grew its position in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 3,018 shares in the last quarter. E Fund Management Co. Ltd. purchased a new stake in shares of Xencor in the second quarter valued at approximately $79,000. Norges Bank acquired a new stake in shares of Xencor in the fourth quarter valued at approximately $175,000. Finally, Prelude Capital Management LLC acquired a new stake in shares of Xencor in the third quarter valued at approximately $139,000.

Analysts Set New Price Targets

A number of research firms have weighed in on XNCR. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Cantor Fitzgerald boosted their price target on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Wedbush lifted their target price on shares of Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Monday, May 11th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $24.86.

Xencor Stock Up 1.5%

NASDAQ:XNCR opened at $28.88 on Friday. Xencor, Inc. has a 52 week low of $7.83 and a 52 week high of $30.61. The stock’s fifty day moving average is $19.54 and its two-hundred day moving average is $14.69. The company has a market capitalization of $2.15 billion, a P/E ratio of -13.31 and a beta of 0.85.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. The business had revenue of $51.22 million during the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The company’s revenue was up 17.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.41) EPS. Sell-side analysts anticipate that Xencor, Inc. will post -3 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.